INC Research Holdings Inc (NASDAQ:INCR) stock price target increased to $57.00, issued a research note today by Zacks Investment Research
- Updated: November 26, 2016
Boasting a price of $50.75, INC Research Holdings Inc (NASDAQ:INCR) traded 0.19% higher on the day. With the last stock price close up 16.75% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.03% over the date range. INC Research Holdings Inc has recorded a 50-day average of $47.16 and a two hundred day average of $44.03. Volume of trade was down over the average, with 115,757 shares of INCR changing hands under the typical 536,250
In a statement issued on 11/22/2016 Zacks Investment Research upped the price target of INC Research Holdings Inc (NASDAQ:INCR) to $57.00 stating a potential upside of 0.12%.
On Friday February 26, 2016, Jefferies & Co released a statement for INC Research Holdings Inc (NASDAQ:INCR) bumped down the target price from $53.00 to $50.00 that suggested an upside of 0.25%.
With a total market value of $0, INC Research Holdings Inc has price-earnings ratio of 27.28 with a one year low of $34.19 and a one year high of $57.11 .
A total of 7 equity analysts have released a ratings update on INCR. Three equity analysts rating the company a strong buy, four equity analysts rating the company a buy, three equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $52.43.
Brief Synopsis About INC Research Holdings Inc (NASDAQ:INCR)
INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company's Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company's Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.